Labiotech.eu

News and Trends 7 Mar 2017

A New Transatlantic Partnership takes on Antibiotic Resistance

The Swiss biotech BioVersys and the US company Aptuit have entered a new collaboration to target antibiotic resistances. BioVersys, based in Basel, is developing small molecules that interfere with bacterial resistance mechanisms. Its current research is focused on nosocomial infections (hospital infections) and tuberculosis. To advance the development of compounds against novel targets identified by BioVersys, the company has […]

March 7, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 6 Mar 2017

The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene

How is biotech in Wales? We take a look at some companies based in the ‘Land of Song,’ their plans and their achievements. After taking a look at the vibrant biotech clusters in the UK like London and Cambridge and picking the top biotechs in Scotland, it’s time to direct our attention to the western part […]

March 6, 2017 - 4 minutesmins - By External Contributor

Interview 6 Mar 2017

How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains

We talked to the CEO of Bicycle Therapeutics, Kevin Lee, about how his company’s technology could cure not just cancer but also a raft of other diseases. Bicycle Therapeutics made a splashy debut in 2014 with a €25M fundraising round, only to outdo it with a €1B deal with AstraZeneca last fall. What’s the fuss? […]

March 6, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 4 Mar 2017

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

Johanna Rotko creates living art with yeast to explore the perishableness of matter and how we interact with nature around us. Johanna Rotko is a visual artist and photographer based in Kotka, Finland, that decided to explore alternative photographic methods. The result were yeastograms, living images made with yeast on petri dishes that disappear over […]

March 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

HIV vaccine University Oxford IrsiCaixa AIDS

News and Trends 3 Mar 2017

An HIV Vaccine Eliminates the Virus in a Patient for 7 Months

An HIV vaccine developed at the University of Oxford has kept 5 out of 15 patients completely free of HIV. One of the patients has already been clear for 7 months. AIDS affects over 36.7 million people. Antiretroviral therapy (ART) is the most common treatment, which kills those cells in which the virus is active. However, HIV can remain inactive and […]

March 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

electronic plants e plants bioelectronics Linköping

More News! 3 Mar 2017

Plants go Electronic with new Swedish Magic Sauce

e-Plants can become a reality with a new technique that creates in vivo electronic circuits. But what are these bioelectronic plants for? A research team from the Linköping University has developed a ‘magic sauce’ that can transform the normal vascular system, through which they transport water and nutrients from the roots, into an electronic circuit. […]

March 3, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 2 Mar 2017

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

Illumina’s cancer diagnostics baby, GRAIL, has raked in a jaw-dropping $1B in Series B. Should Europe get on America’s level? A new genome sequencing company spun out of Illumina, GRAIL, has raised over $900M in a Series B fundraising round. That’s far and away the largest round ever; further, that’s more than most companies hope to be worth, […]

March 2, 2017 - 5 minutesmins - By Evelyn Warner

More News! 1 Mar 2017

German Spin-off Scores Funding to Treat Atrial Fibrillation

The Berlin-based startup OMEICOS Therapeutics announced the first closing of a series B financing round of €8.3M and the initiation of a Phase 1 clinical trial for the treatment of atrial fibrillation. OMEICOS Therapeutics, a spin-off from the Max Delbrueck Center for Molecular Medicine in Berlin, is taking the next step with its lead compound OMT-28 for […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 1 Mar 2017

Swedish Oncology Biotech makes a Large IPO for its Peptides

The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and is focused on the development of its lead compound Ygalo. After the company started a Phase II trial in patients with late stage relapsed and refractory multiple […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

cultured meat market 2020 1 e1488366878713

More News! 1 Mar 2017

Lab-Grown Meat Could Hit the Market as Soon as 2020

Cultured meat could be a sustainable, healthy and inexpensive food alternative in a future that might be closer than we think. We recently attended the 2nd International Conference on Cultured Meat, where we had the chance to meet the key players in this revolutionary field. There, we learned that cultured meat, grown in the lab without […]

March 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Mar 2017

Scaling Up your Drug? Follow these 3 Steps to Succeed

As a biotech scales up from the lab to industry, data management is a key part of the process. Even if you manage to prove your concept, applying it to patients will increase the number of variables in the business process calculations exponentially. How do you keep track of them all? In the development of […]

March 1, 2017 - 5 minutesmins - By External Contributor

AC Immune Genentech crenezumab phase III

News and Trends 28 Feb 2017

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up with Genentech to bring its amyloid beta (Aβ)-targeting antibody crenezumab into the clinic. Although the compound did not meet its co-primary enpoints in the large phase II ABBY trial, Genentech pushed […]

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

A New Transatlantic Partnership takes on Antibiotic Resistance

The ‘Underdog of the UK?’ 8 Companies Proving the Welsh Biotech Scene

How did this Biotech seal a €1B Deal with AstraZeneca? The CEO Explains

Meet the Finnish Bioartist using Yeast to Create Vanishing Photographs

An HIV Vaccine Eliminates the Virus in a Patient for 7 Months

Plants go Electronic with new Swedish Magic Sauce

There’s a New Record in Biotech Fundraising: Should We Believe the Hype?

German Spin-off Scores Funding to Treat Atrial Fibrillation

Swedish Oncology Biotech makes a Large IPO for its Peptides

Lab-Grown Meat Could Hit the Market as Soon as 2020

Scaling Up your Drug? Follow these 3 Steps to Succeed

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!